Tjoapack Expands in the U.S. and Europe

Live From Show Updates

Lifecore Supports Drug/Device Combo for Acne Treatment 

To produce and supply engineering and clinical batches of DT-001 for planned Phase II trials.

SPONSOR

Streamline HME Projects with Early Partner Engagement

Hot-melt extrusion (HME) is an advantageous method for enhancing the solubility and bioavailability of poorly soluble active pharmaceutical ingredients (APIs) — if the formulation is robust and scalable. Partnering early on with an experienced CDMO can help accelerate the development of optimal, scalable, and patient-centric HME products.

Live From Show Updates

HIPRA Biotech Expands Biologics Capacity 

Launches new R&D building, commissions GMP microbial fermentation facility, and new QC labs.

Live From Show Updates

Clariant Expands Pharma-grade PEG Manufacturing into North America 

To manufacture polyethylene glycol excipients for oral and topical applications at Clear Lake, TX site.

SPONSOR

Looking for a Solid Oral Dose CMO?

Meet with Ropack Pharma Solutions in New York at DCAT 2026. Let’s discuss how we can support your next project.

Live From Show Updates

LGM Pharma Invests Additional $9M in Texas and Colorado Facilities

Will increase commercial capacity, expand R&D capabilities, to support continued demand for U.S.-based drug product manufacturing.

Live From Show Updates

SGD Pharma, Prince Sterilization Partner on North American Pharmaceutical Glass Offering 

Prince to validate SGD’s Ready-to-Use Type I glass primary packaging solutions for North American market.

SPONSOR

Meet the makers of more tomorrows at DCAT Week

Discover how Kindeva helps bring life-changing therapies to patients faster. Meet us March 23–26.

SPONSOR

Bring us your batch. We’ll deliver.

Complex molecule? Difficult process? We’re your people. We’ve got a decades-long history of problem solving and fear-no-challenge culture.

SPONSOR

Ahead of DCAT Week, IPP Offers Unique Capital-Light Route into World-Class API Manufacturing Capacity

International Process Plants (IPP) announces a direct path into commercial volume small molecule API manufacturing for pharmaceutical & CDMO companies at its Grimsby, UK platform—without the capital burden of acquisition or greenfield buildout.